BRAC

Dhaka, Bangladesh
Dhaka, Bangladesh
SEARCH FILTERS
Time filter
Source Type

News Article | April 17, 2017
Site: www.eurekalert.org

Escaping cycles of poverty may depend on how much a person feels he or she can rely on their local communities, according to research led by Princeton University. Published in the Proceedings of the National Academy of Sciences, the study finds that low-income individuals who trust their communities make better long-term financial decisions. This is likely because citizens rely on friends and neighbors for financial support, rather than quick fixes, like payday loans, which further indebt them. The findings show the importance of building strong communities, especially for low-income individuals. The researchers suggest moving away from a focus on low-income individuals, instead focusing on low-income communities through targeted policies. "Instead of cutting funding to community development programs, policymakers should implement changes that give individuals in low-income communities more opportunities to develop community trust," said study co-author Elke Weber, the Gerhard R. Andlinger Professor in Energy and the Environment and professor of psychology and public affairs at Princeton University's Woodrow Wilson School. In addition to Weber, the study was conducted by lead author Jon Jachimowicz, Columbia University; Salah Chafik, Columbia University; Sabeth Munrat, BRAC (an international development organization in Bangladesh); and Jaideep Prabhu, University of Cambridge. To determine why low-income individuals tend to make more myopic (or short-term) financial decisions, the researchers conducted a series of studies, focusing on both the United States and Bangladesh. In the first study, the researchers invited 647 participants from the United States to make several choices between "smaller, sooner" and "larger, later" options, taking into account participants' incomes and how much they trusted their local communities. They found that richer participants were generally less likely to make harmful short-term decisions than those with lower incomes, but that this only applied to low-income individuals who did not trust their communities. In contrast, those low-income individuals who trust their communities more made financial decisions that were very similar to those made by richer participants. "Current financial dilemmas are stressful and leave people with no option but to choose immediate solutions. Our results indicate that lower-income people are less likely to invest in the long-term because of their immediate financial needs," said Weber. "This is in line with work by Princeton's Eldar Shafir and others: that scarcity leads to harmful long-term decision-making." In the second study, the researchers evaluated "payday loans" in the United States, which carry high interest rates and exacerbate cycles of poverty among the poor. After reviewing the Federal Reserve Board's Survey of Household Economics and Decisionmaking, the researchers found that fewer payday loans were taken out in communities where levels of trust were higher. This is because individuals can rely on their communities to help with financial needs (taking out a loan from a friend, for example), instead of resorting to high-interest emergency loans, the researchers said. In the final part of the study, the researchers turned their attention to Bangladesh, where they conducted a two-year field study. Together with BRAC and The Hunger Project, a global nonprofit organization, the researchers worked with 121 of Bangladesh's smallest local government units, known as council unions. They trained community volunteers to act as intermediaries between local government and community residents. Volunteers met with members of their community and helped provide them with access to public services. Volunteers also provided guidance to government units directly. When comparing the unions with community volunteers to those without, the researchers found the two groups differed widely in their levels of community trust. Residents with community volunteers had higher levels of community trust, which also influenced their decision-making. These individuals were more likely to forgo smaller payoffs in exchange for more-profitable, delayed options. Taken together, the findings highlight the importance of building trust in low-income communities. The findings also point to the benefits of programs currently targeted for budget cuts by the Trump administration, the researchers said. "The Trump administration's preliminary federal budget for 2018 recommends eliminating the $3 billion Community Development Block Grant, a program established in 1974 to help communities address a wide range of their development needs," said Jachimowicz. "The budget blueprint reasons that the program is 'not well-targeted to the poorest populations and has not demonstrated results.' The evidence presented in our paper contradicts this claim, and suggests eliminating this line item could lead to devastating consequences, particularly for those on low incomes." The paper, "Community trust reduces myopic decisions of low-income individuals," was published online in PNAS on April 11. This research was made possible in part by a Cambridge Judge Business School small grant, the research facilities provided by the Center for Decision Sciences at Columbia University and the support of the German National Academic Foundation.


This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. This report highlights a number of significant pharmacos and gives details of their operations, products, financials and business strategy. The personalized medicine (global & USA) market is presented as follows: By Company (e.g., Qiagen, AFFYMETRIX, ATOSSA GENETICS, NODALITY, deCode /Amgen, CELERA, MYRIAD) By Segment (Targeted therapeutics, Companion Diagnostics, Liquid Biopsies) By Sub-market (Companion diagnostic, targeted cancer therapeutic, medical technology, pharmacogenomics, consumer genomics, molecular diagnostics, liquid biopsy) By Therapy (Cancer, Cardiovascular, Infectious Disease) Key Opinion Leaders that contributed to interview questions within the report include: - Iain D. Miller, PhD, MBA, Founder & CEO, Healthcare Strategies Group - Stephen Finn, MBBS, PhD, Associate Professor, Cancer Molecular Diagnostic Laboratory, Consultant Histopathologist and Head of Histopathology, St James's Hospital and Trinity College Dublin, Ireland - Ronald Przygodzki, MD, Director, Genomic Medicine Implementation at U.S. Department of Veterans Affairs, Washington DC - Elaine Kenny, PhD, Founder, Elda Biotech, Dublin 2, Ireland - Chad Clark, Co-President and Chief Operating Officer, Precision for Medicine - Tobias Guennel, PhD, Principal, Biomarker and IVD Analytics, Precision for Medicine - David Parker, PhD, Vice President, Integrated Market Access, Precision for Medicine - Deborah Phippard, PhD, Vice President, Research, Precision for Medicine - Judi Smith, MS, Vice President, In Vitro Diagnostics Regulatory and Quality, Precision for Medicine A wealth of financial data & business strategy information is provided including: - Company financials, sales & revenue figures - Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies - Business Model Strategies for Providers. Provider Systems and Academic Medical Centres - Business Model Strategies for Payers & Governments - Private and Public Funding and Personalized Medicine Reimbursement - Revisions to Current Payment Systems and intellectual property - How to Gain Market Penetration in the EU - Cost-effectiveness and Business Value of Personalized Medicine - Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations) - Comprehensive account of company product portfolios & kits SWOT, Economic & Regulatory Environment specifics include: - Key strengths, weaknesses and threats influencing leading player position within the market - Technologies driving the market (e.g., New-Generation Sequencing Technologies, Ultra-High Throughput Sequencing) - Top fastest growing market segments and emerging opportunities - Top pharmaceutical companies within the IPM by market share and revenue - Comprehensive product portfolios, R&D activity and pipeline therapeutics - M&A activity and future strategies of top personalized medicine pharmacos - Personalized Medicine Regulation (USA, UK, Germany, France, Spain, Italy) - CE-marked Personalized Medicine/Diagnostic Tests - FDA Advances in Personalized Medicine Regulation What you will gain: - An in-depth understanding of the global personalized medicine market and it's environment - Current market facts, figures and product lines of key players in the industry - Emerging trends in key markets such as the US, UK, Germany and France - Knowledge of how the personalized medicine market will integrate into the global healthcare market - Technical insights into new generation sequencing technologies and ultra-high throughput sequencing - Updates on bioinformatics, high throughput systems, genetic analysis kits, companion diagnostics and future technologies - FDA approved pharmacogenetic tests and recognized biomarkers - Information on key government and regulatory policies - Strategies on how to adapt and restructure current business models to this industry This report tackles key concerns to the personalized medicine market such as: - Lack of regulatory policy and legislation in the US and Europe - Reimbursement schemes and payers concerns - Transition of investigational diagnostic assays and therapeutics to clinical practice - Direct to consumer (DTC) test kits and implications for the public This report will tell you if the companies mentioned are: - Strong, competitive players - Pooling their resources for specific growth and therapeutic areas - Investing strategically in R&D - Have a history of strategic M&A activity Key Topics Covered: 1.0 Executive Summary 2.0 Introduction and Background 3.0 Personalized Medicine Targeted Therapeutics and Associated Companion Diagnostics 4.0 Personalized Medicine and Integration into the Healthcare System 5.0 Private and Public Funding and Personalized Medicine Reimbursement 6.0 European Personalized Medicine Market - Payments and Investment 7.0 Personalized Medicine -Business Model Analysis 8.0 Personalized Medicine Main Industry Players 9.0 Personalized Medicine Market Analysis 10.0 Strengths and Advantages of Personalized Medicine 11.0 Restraints of the Personalized Medicine Market 12.0 Personalized Medicine and Regulatory Policies 13.0 Final Summary and Future Perspectives 14.0 Interviews with Key Opinion Leaders Companies Mentioned For more information about this report visit http://www.researchandmarkets.com/research/wk98zk/personalized Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/global-personalized-medicine-targeted-therapeutics-and-companion-diagnostic-market-2017-2021-strategic-analysis-of-industry-trends-technologies-participants-and-environment---research-and-markets-300460730.html


Dublin, May 24, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market to 2021- Strategic Analysis of Industry Trends, Technologies, Participants, and Environment" report to their offering. This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by over 360 tables & figures over 397 pages. The personalized medicine (global & USA) market is presented as follows: By Company (e.g., Qiagen, AFFYMETRIX, ATOSSA GENETICS, NODALITY, deCode /Amgen, CELERA, MYRIAD) By Segment (Targeted therapeutics, Companion Diagnostics, Liquid Biopsies) By Sub-market (Companion diagnostic, targeted cancer therapeutic, medical technology, pharmacogenomics, consumer genomics, molecular diagnostics, liquid biopsy) By Therapy (Cancer, Cardiovascular, Infectious Disease) Key Opinion Leaders that contributed to interview questions within the report include: - Iain D. Miller, PhD, MBA, Founder & CEO, Healthcare Strategies Group - Stephen Finn, MBBS, PhD, Associate Professor, Cancer Molecular Diagnostic Laboratory, Consultant Histopathologist and Head of Histopathology, St James's Hospital and Trinity College Dublin, Ireland - Ronald Przygodzki, MD, Director, Genomic Medicine Implementation at U.S. Department of Veterans Affairs, Washington DC - Elaine Kenny, PhD, Founder, Elda Biotech, Dublin 2, Ireland - Chad Clark, Co-President and Chief Operating Officer, Precision for Medicine - Tobias Guennel, PhD, Principal, Biomarker and IVD Analytics, Precision for Medicine - David Parker, PhD, Vice President, Integrated Market Access, Precision for Medicine - Deborah Phippard, PhD, Vice President, Research, Precision for Medicine - Judi Smith, MS, Vice President, In Vitro Diagnostics Regulatory and Quality, Precision for Medicine A wealth of financial data & business strategy information is provided including: - Company financials, sales & revenue figures - Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies - Business Model Strategies for Providers. Provider Systems and Academic Medical Centres - Business Model Strategies for Payers & Governments - Private and Public Funding and Personalized Medicine Reimbursement - Revisions to Current Payment Systems and intellectual property - How to Gain Market Penetration in the EU - Cost-effectiveness and Business Value of Personalized Medicine - Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations) - Comprehensive account of company product portfolios & kits SWOT, Economic & Regulatory Environment specifics include: - Key strengths, weaknesses and threats influencing leading player position within the market - Technologies driving the market (e.g., New-Generation Sequencing Technologies, Ultra-High Throughput Sequencing) - Top fastest growing market segments and emerging opportunities - Top pharmaceutical companies within the IPM by market share and revenue - Comprehensive product portfolios, R&D activity and pipeline therapeutics - M&A activity and future strategies of top personalized medicine pharmacos - Personalized Medicine Regulation (USA, UK, Germany, France, Spain, Italy) - CE-marked Personalized Medicine/Diagnostic Tests - FDA Advances in Personalized Medicine Regulation This report highlights a number of significant pharmacos and gives details of their operations, products, financials and business strategy. What you will gain: - An in-depth understanding of the global personalized medicine market and it's environment - Current market facts, figures and product lines of key players in the industry - Emerging trends in key markets such as the US, UK, Germany and France - Knowledge of how the personalized medicine market will integrate into the global healthcare market - Technical insights into new generation sequencing technologies and ultra-high throughput sequencing - Updates on bioinformatics, high throughput systems, genetic analysis kits, companion diagnostics and future technologies - FDA approved pharmacogenetic tests and recognized biomarkers - Information on key government and regulatory policies - Strategies on how to adapt and restructure current business models to this industry This report tackles key concerns to the personalized medicine market such as: - Lack of regulatory policy and legislation in the US and Europe - Reimbursement schemes and payers concerns - Transition of investigational diagnostic assays and therapeutics to clinical practice - Direct to consumer (DTC) test kits and implications for the public Who should read this report? - Pharmaceutical, biotechnology and diagnostic companies (CEOs, VPs, Business Development, C-Suite)with an interest in personalized medicine - Industry professionals and business strategists will discover key information to propel their policies - Investors will gain inside information to dominant players in the industry and future forecasts - Scientists will get a business perspective and industry insight into how scientific breakthroughs influence the market environment This report will tell you if the companies mentioned are: - Strong, competitive players - Pooling their resources for specific growth and therapeutic areas - Investing strategically in R&D - Have a history of strategic M&A activity Key Topics Covered: 1.0 Executive Summary 2.0 Introduction and Background 3.0 Personalized Medicine Targeted Therapeutics and Associated Companion Diagnostics 4.0 Personalized Medicine and Integration into the Healthcare System 5.0 Private and Public Funding and Personalized Medicine Reimbursement 6.0 European Personalized Medicine Market - Payments and Investment 7.0 Personalized Medicine -Business Model Analysis 8.0 Personalized Medicine Main Industry Players 14.0 Interviews with Key Opinion Leaders Companies Mentioned - 23andMe - Abbott Laboratories - Abbott Molecular Inc. - Admera Health (GENEWIZ) - Affymetrix - Agendia - Alere - Amgen - Astex Pharmaceuticals - AstraZeneca - Atossa Genetics - Becton Dickenson - bioMerieux - BristolMyersSquibb - Cancer Genetics - Celera (Quest Diagnostics) - Celldex Therapeutics - Claritas Genomics - CuraGen - Danaher (Leica Biosystems) - deCode Genetics (Amgen) - EDP Biotech - ELDA BioTech - Eisai - Eli Lilly - Foundation Medicine - Genelex - GlaxoSmithKline - HalioDx - Human Longevity Inc (Cypher Genomics) - Ikonisys - Illumina - InterGenetics - Johnson & Johnson - LabCorp - Life Technologies - MDxHealth - Merck - MolecularMD Corporation - Monogram Biosciences - Myriad - NanoString Technologies - Nodality - Novartis MDx - Orion Genomics - Oxford BioTherapeutics - Pfizer - Qiagen - Roche Molecular Diagnostics - Sanofi - SensiGen - Siemens Healthcare Diagnostics - Takeda - Thermo Fisher Scientific - Transgenomic - Ventana (Roche) - Vermillion (Ciphergen) - Vertex Pharmaceuticals For more information about this report visit http://www.researchandmarkets.com/research/zbw7h4/personalized


Dublin, May 24, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market to 2021- Strategic Analysis of Industry Trends, Technologies, Participants, and Environment" report to their offering. This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by over 360 tables & figures over 397 pages. The personalized medicine (global & USA) market is presented as follows: By Company (e.g., Qiagen, AFFYMETRIX, ATOSSA GENETICS, NODALITY, deCode /Amgen, CELERA, MYRIAD) By Segment (Targeted therapeutics, Companion Diagnostics, Liquid Biopsies) By Sub-market (Companion diagnostic, targeted cancer therapeutic, medical technology, pharmacogenomics, consumer genomics, molecular diagnostics, liquid biopsy) By Therapy (Cancer, Cardiovascular, Infectious Disease) Key Opinion Leaders that contributed to interview questions within the report include: - Iain D. Miller, PhD, MBA, Founder & CEO, Healthcare Strategies Group - Stephen Finn, MBBS, PhD, Associate Professor, Cancer Molecular Diagnostic Laboratory, Consultant Histopathologist and Head of Histopathology, St James's Hospital and Trinity College Dublin, Ireland - Ronald Przygodzki, MD, Director, Genomic Medicine Implementation at U.S. Department of Veterans Affairs, Washington DC - Elaine Kenny, PhD, Founder, Elda Biotech, Dublin 2, Ireland - Chad Clark, Co-President and Chief Operating Officer, Precision for Medicine - Tobias Guennel, PhD, Principal, Biomarker and IVD Analytics, Precision for Medicine - David Parker, PhD, Vice President, Integrated Market Access, Precision for Medicine - Deborah Phippard, PhD, Vice President, Research, Precision for Medicine - Judi Smith, MS, Vice President, In Vitro Diagnostics Regulatory and Quality, Precision for Medicine A wealth of financial data & business strategy information is provided including: - Company financials, sales & revenue figures - Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies - Business Model Strategies for Providers. Provider Systems and Academic Medical Centres - Business Model Strategies for Payers & Governments - Private and Public Funding and Personalized Medicine Reimbursement - Revisions to Current Payment Systems and intellectual property - How to Gain Market Penetration in the EU - Cost-effectiveness and Business Value of Personalized Medicine - Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations) - Comprehensive account of company product portfolios & kits SWOT, Economic & Regulatory Environment specifics include: - Key strengths, weaknesses and threats influencing leading player position within the market - Technologies driving the market (e.g., New-Generation Sequencing Technologies, Ultra-High Throughput Sequencing) - Top fastest growing market segments and emerging opportunities - Top pharmaceutical companies within the IPM by market share and revenue - Comprehensive product portfolios, R&D activity and pipeline therapeutics - M&A activity and future strategies of top personalized medicine pharmacos - Personalized Medicine Regulation (USA, UK, Germany, France, Spain, Italy) - CE-marked Personalized Medicine/Diagnostic Tests - FDA Advances in Personalized Medicine Regulation This report highlights a number of significant pharmacos and gives details of their operations, products, financials and business strategy. What you will gain: - An in-depth understanding of the global personalized medicine market and it's environment - Current market facts, figures and product lines of key players in the industry - Emerging trends in key markets such as the US, UK, Germany and France - Knowledge of how the personalized medicine market will integrate into the global healthcare market - Technical insights into new generation sequencing technologies and ultra-high throughput sequencing - Updates on bioinformatics, high throughput systems, genetic analysis kits, companion diagnostics and future technologies - FDA approved pharmacogenetic tests and recognized biomarkers - Information on key government and regulatory policies - Strategies on how to adapt and restructure current business models to this industry This report tackles key concerns to the personalized medicine market such as: - Lack of regulatory policy and legislation in the US and Europe - Reimbursement schemes and payers concerns - Transition of investigational diagnostic assays and therapeutics to clinical practice - Direct to consumer (DTC) test kits and implications for the public Who should read this report? - Pharmaceutical, biotechnology and diagnostic companies (CEOs, VPs, Business Development, C-Suite)with an interest in personalized medicine - Industry professionals and business strategists will discover key information to propel their policies - Investors will gain inside information to dominant players in the industry and future forecasts - Scientists will get a business perspective and industry insight into how scientific breakthroughs influence the market environment This report will tell you if the companies mentioned are: - Strong, competitive players - Pooling their resources for specific growth and therapeutic areas - Investing strategically in R&D - Have a history of strategic M&A activity Key Topics Covered: 1.0 Executive Summary 2.0 Introduction and Background 3.0 Personalized Medicine Targeted Therapeutics and Associated Companion Diagnostics 4.0 Personalized Medicine and Integration into the Healthcare System 5.0 Private and Public Funding and Personalized Medicine Reimbursement 6.0 European Personalized Medicine Market - Payments and Investment 7.0 Personalized Medicine -Business Model Analysis 8.0 Personalized Medicine Main Industry Players 14.0 Interviews with Key Opinion Leaders Companies Mentioned - 23andMe - Abbott Laboratories - Abbott Molecular Inc. - Admera Health (GENEWIZ) - Affymetrix - Agendia - Alere - Amgen - Astex Pharmaceuticals - AstraZeneca - Atossa Genetics - Becton Dickenson - bioMerieux - BristolMyersSquibb - Cancer Genetics - Celera (Quest Diagnostics) - Celldex Therapeutics - Claritas Genomics - CuraGen - Danaher (Leica Biosystems) - deCode Genetics (Amgen) - EDP Biotech - ELDA BioTech - Eisai - Eli Lilly - Foundation Medicine - Genelex - GlaxoSmithKline - HalioDx - Human Longevity Inc (Cypher Genomics) - Ikonisys - Illumina - InterGenetics - Johnson & Johnson - LabCorp - Life Technologies - MDxHealth - Merck - MolecularMD Corporation - Monogram Biosciences - Myriad - NanoString Technologies - Nodality - Novartis MDx - Orion Genomics - Oxford BioTherapeutics - Pfizer - Qiagen - Roche Molecular Diagnostics - Sanofi - SensiGen - Siemens Healthcare Diagnostics - Takeda - Thermo Fisher Scientific - Transgenomic - Ventana (Roche) - Vermillion (Ciphergen) - Vertex Pharmaceuticals For more information about this report visit http://www.researchandmarkets.com/research/zbw7h4/personalized

Loading BRAC collaborators
Loading BRAC collaborators